Researchers at Emory University reported in Nature Microbiology in September 2026 that venetoclax — a medication already approved for treating certain types of leukaemia — reduced the SIV reservoir in nonhuman primates. It is the first proof-of-concept for eliminating HIV-infected cells using this specific mechanism.
What is the viral reservoir?
Antiretroviral therapy stops HIV from replicating. It does not eliminate the virus from the body. Small pockets of HIV-infected cells — mostly immune cells called CD4+ T cells — remain hidden in tissues. These cells are not producing virus, so the immune system does not see them and the drugs do not touch them.
This is why HIV treatment is lifelong. If you stop taking medication, the reservoir reawakens and the virus returns.
Shrinking or eliminating the reservoir is the single biggest challenge in cure research.
Why venetoclax
Venetoclax works by blocking a protein called BCL-2. That protein normally keeps cells alive by preventing programmed cell death (apoptosis). Cancer cells often overproduce BCL-2 to avoid dying, which is why venetoclax works against certain leukaemias.
HIV-infected cells in the reservoir also overproduce BCL-2. Researchers hypothesised that if they blocked BCL-2 in these cells, they might push the reservoir cells to die.
What the study found
The Emory team tested this in nonhuman primates infected with SIV (the primate equivalent of HIV). Animals treated with venetoclax on top of standard antiretroviral therapy showed a significant reduction in the size of the viral reservoir compared to animals on antiretroviral therapy alone.
The reduction was measurable and sustained. It was not elimination of the reservoir, but it was the first time this approach had worked in a living animal.
Why this matters
Three reasons:
- It uses an already-approved drug. Venetoclax is on the market. The safety profile in humans is already known. That significantly shortens the path to clinical trials in people living with HIV.
- It targets a specific vulnerability. Not all reservoir cells are the same. This approach targets the ones that depend on BCL-2 for survival. That could be combined with other approaches that target different cell populations.
- It opens a new research direction. For years, the field has focused on "shock and kill" strategies — reactivating the virus so the immune system or drugs can kill the infected cells. Venetoclax is a different approach: forcing the reservoir cells to die without reactivating the virus first.
What comes next
The Emory team will now need to test this in human trials. There are real risks: venetoclax suppresses some immune cell populations, which could leave patients vulnerable to infections. The dose and duration used in a cure setting would need to be carefully studied.
If Phase 1 human trials begin, expect them within 18–24 months. Even if they are successful, a venetoclax-based cure strategy is likely years away from clinical use.
The bigger picture
HIV cure research has historically been marked by disappointment. Most strategies that work in the lab fail in humans. But the field is now producing multiple approaches that reduce the reservoir in animal models — venetoclax, therapeutic vaccines, broadly neutralising antibodies, and gene editing. Each one moves the field a small step closer.
Haven is a dating and community app built for the HIV+ community in South Africa.
Get Haven on Google Play